Jury upholds three Repatha patent claims

A jury upheld the validity of three of the five asserted claims covering two U.S. patents for PCSK9 inhibitor Repatha evolocumab from Amgen Inc. (NASDAQ:AMGN).

The jury found two of the claims of U.S. Patent No. 8,829,165 to be invalid based on lack of written description, but upheld a third claim. It upheld both asserted claims of U.S. Patent No. 8,859,741...